Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells

Immunity

Volumn 10, Issue 1, 1999, Pages 105-115

  Catlett Falcone, Robyn ^a,c   Landowski, Terry H ^b,d   Oshiro, Marc M ^b,d   Turkson, James ^a,c   Levitzki, Alexander ^e   Savino, Rocco ^f   Ciliberto, Gennaro ^f   Moscinski, Lynn ^c   Fernández Luna, Jose Luis ^g   Nuñez, Gabriel ^h   Dalton, William S ^b,c,d   Jove, Richard ^a,c  

^a Molecular Oncology Program   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c Department of Pathology ^*  (United States)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

^e HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^f IRBM   (Italy)

^g HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^h UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; STAT3 PROTEIN;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; PATHOGENESIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 0032984589     PISSN: 10747613     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1074-7613(00)80011-4     Document Type: Article

References (56)

1. Akira, S., Nishio, Y., Inoue, M., Wang, X.J., Wei, S., Matsusaka, T., Yoshida, K., Sudo, T., Naruto, M., and Kishimoto, T. (1994). Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91 -related transcription factor involved in the gp130-mediated signaling pathway. Cell 77, 63-71.
2. Boise, L.H., and Thompson, C.B. (1997). Bcl-xl can inhibit apoptosis in cells that have undergone Fas-induced protease activation. Proc. Natl. Acad. Sci. USA 94, 3759-3764.
3. Boise, L.H., González-Garcia, M., Postema, C.E., Ding, L, Lindsten, T., Turka, L.A., Mao, X., Nuñez, G., and Thompson, C.B. (1993). Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74, 597-608.
4. Bromberg, J.F., Horvath, C.M., Besser, D., Lathem, W.W., and DarNell, J.E. (1998). Stat3 activation is required for cellular transformation by v-src. Mol. Cell. Biol. 18, 2553-2558.
5. Caldenhoven, E., van Dijk, T.B., Solari, R., Armstrong, J., RaaijmakErs, J.A.M., Lammers, J.W.J., Koenderman, L., and de Groot, R.P. (1996). Stat3beta, a splice variant of transcription factor STAT3, is a dominant negative regulator of transcription. J. Biol. Chem. 271, 13221-13227.
6. Cao, X., Tay, A., Guy, G.R., and Tan, Y.H. (1996). Activation and association of Stat3 with Src in v-Src-transformed cell lines. Mol. Cell. Biol. 16, 1595-1603.
7. Chai, S.K., Nichols, G.L., and Rothman, P. (1997). Constitutive activation of jaks and stats in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients. J. Immunol. 159, 4720-4728.
8. Chao, D.T., Linette, G.P., Boise, L.H., White, L.S., Thompson, C.B., and Korsmeyer, S.J. (1995). Bcl-xl and Bcl-2 repress a common pathway of cell death. J. Exp. Med. 182, 821-828.
9. Chaturvedi, P., Sharma, S., and Reddy, E.P. (1997). Abrogation of interleukin-3 dependence of myeloid cells by the v-src oncogene requires SH2 and SH3 domains which specify activation of STATs. Mol. Cell. Biol. 17, 3295-3304.
10. Chauhan, D., Kharbanda, S., Ogata, A., Urashima, M., Teoh, G., Robertson, M., Kufe, D.W., and Andersen, K.C. (1997). Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells. Blood 89, 227-234.
11. Danial, N.N., Pernis, A., and Rothman, P. (1995). Jak-STAT signaling induced by the v-abl oncogene. Science 269, 1875-1877.
12. Darnell, J.E. (1997). stats and gene regulation. Science 277,1630-1635.
13. Darnell, J.E., Kerr, I.M., and Stark, G.R. (1994). Jak-stat pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264, 1415-1421.
14. Fujio, Y., Kunisada, K., Hirota, H., Yamauchi-Takihara, K., and KishiMoto, T. (1997). Signals through gp130 upregulate bcl-x gene expression via STAT1-binding cis-element in cardiac myocytes. J. Clin. Invest. 99, 2898-2905.
15. Fukada, T., Hibi, M., Yamanaka, Y., Takahashi-Tezuka, M., Fujitani, Y., Yamaguchi, T., Nakajima, K., and Hirano, T. (1996). Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: Involvement of STAT3 in anti-apoptosis. Immunity 5, 449-460.
16. Garcia, R., and Jove, R. (1998). Activation of STAT transcription factors in oncogenic tyrosine kinase signaling. J. Biomed. Sci. 5, 79-85.
17. Garcia, R., Yu, C.L., Hudnall, A., Catlett, R., Nelson, K.L., Smithgall, T., Fujita, D.J., Ethier, S.P., and Jove, R. (1997). Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth Diff. 8, 1267-1276.
18. Gouilleux-Gruart, V., Gouilleux, F., Desaint, C., Claisse, J.F., Capiod, J.C., Delobel, J., Weber-Nordt, R., Dusanter-Fourt, I., Dreyfus, F., Groner, B., and Prin, L. (1996). Stat-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients. Blood 87, 1692-1697.
19. Grillot, D.A., González-Garcia, M., Ekhterae, D., Duan, L., Inohara, N., Ohta, S., Seidin, M.F., and Nuñez, G. (1997). Genomic organization, promoter region analysis, and chromosome localization of the mouse bcl-x gene. J. Immunol. 158, 4750-4757.
20. Hallek, M., Bergsagel, P.L., and Andersen, K.C. (1998). Multiple myeloma: Increasing evidence for a multistep transformation process. Blood 91, 3-21.
21. Ihara, S., Nakajima, K., Fukada, T., Hibi, M., Nagata, S., Hirano, T., And Fukui, Y. (1997). Dual control of neurite outgrowth by STAT3 and MAP kinase in PC12 cells stimulated with interleukin-6. EMBO J. 16, 5345-5352.
22. Ihle, J.N., Witthuhn, B.A., Quelle, F.W., Yamamoto, K., and SilvenNoinen, O. (1995). Signaling through the hematopoietic cytokine receptors. Annu. Rev. Immunol. 13, 369-398.
23. Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato, K., Asaoku, H., Tang, B., Tanabe, O., Tanaka, H., and Kishimoto, T. (1988). Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332, 83-85.
24. Kelekar, A., Chang, B.S., Harlan, J.E., Fesik, S.W., and Thompson, C.B. (1997). Bad is a BH3 domain-containing protein that forms an inactivating dimer with Bcl-XL. Mol. Cell. Biol. 17, 7040-7046.
25. Keller, E.T., and Erschler, W.B. (1995). Effect of IL-6 receptor antisense oligodeoxynucleotide on in vitro proliferation of myeloma cells. J. Immunol. 154, 4091-4098.
26. Klein, B., Zhang, X.G., Lu, Z.Y., and Bataille, R. (1995). Interleukin-6 in human multiple myeloma. Blood 85, 863-872.
27. Landowski, T.H., Qu, N., Buyuksal, I., Painter, J.S., and Dalton, W.S. (1997). Mutations in the Fas antigen in patients with multiple myeloma. Blood 90, 4266-4270.
28. Lichtenstein, A., Tu, Y., Fady, C., Vescio, R., and Berenson, J. (1995). Interleukin-6 inhibits apoptosis of malignant plasma cells. Cell. ImMunol. 162, 248-255.
29. Lund, T.C., Garcia, R., Medveczky, M.M., Jove, R., and Medveczky, P.G. (1997). Activation of STAT transcription factors by herpesvirus saimiri Tip-484 requires p56lck. J. Virol. 71, 6677-6682.
30. Meydan, N., Grunberger, T., Dadi, H., Shahar, M., Arpala, E., Lapidot, Z., Leeder, J.S., Freedman, M., Cohen, A., Gazit, A., Levitzki, A., and Roifman, C.M. (1996). Inhibition of acute lymphoblastic leukemia by a Jak-2 inhibitor. Nature 379, 645-648.
31. Migone, T.S., Lin, J.X., Cereseto, A., Mulloy, J.C., O'Shea, J.J., Franchini, G.,and Leonard, W.J. (1995). Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I. Science 269, 79-81.
32. Nagata, S., and Golstein, P. (1995). The Fas death factor. Science 267, 1449-1456.
33. Ogata, A., Chauhan, D., Teoh, G., Treon, S.P., Urashima, M., SchlossMan, R.L., and Anderson, K.C. (1997). IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J. Immunol. 159, 2212-2221.
34. Reed, J.C. (1997). Double identity for proteins of the Bcl-2 family. Nature 387, 773-776.
35. Sartor, C.I., Dziubinski, M.L., Yu, C.L., Jove, R., and Ethier, S.P. (1997). Role of epidermal growth factor receptor and STAT-3 activation in autonomous proliferation of SUM-102PT human breast cancer cells. Cancer Res. 57, 978-987.
36. Schaefer, T.S., Sanders, L.K., Park, O.K., and Nathans, D. (1997). Functional differences between Stat3α and Stat3β. Mol. Cell. Biol. 17, 5307-5316.
37. Schneider, T.J., Grillot, D., Foote, L.C., Nuñez, G.E., and Rothstein, T.L. (1997). Bcl-x protects primary B cells against Fas-mediated apoptosis. J. Immunol. 159, 4834-4839.
38. Schwab, G., Siegall, C.B., Aarden, L.A., Neckers, L.M., and Nordan, R.P. (1991). Characterization of an interleukin-6-mediated autocrine growth loop in the human multiple myeloma cell line, U266. Blood 77, 587-593.
39. Schwarze, M.M., and Hawley, R.G. (1995). Prevention of myeloma cell apoptosis by ectopic bcl-2 expression or interleukin 6-mediated up-regulation of bcl-xl. Cancer Res. 55, 2262-2265.
40. Seidel, H.M., Milocco, L.H., Lamb, P., Darnell, J.E., Stein, R.B., and Rosen, J. (1995). Spacing of palindromic half sites as a determinant of selective STAT (signal transducers and activators of transcription) DNA binding and transcriptional activity. Proc. Natl. Acad. Sci. USA 92, 3041-3045.
41. Silva, M., Grillot, D., Benito, A., Richard, C., Nuñez, G., and FernánDez-Luna, J.L. (1996). Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through Bcl-XL and Bcl-2. Blood 88, 1576-1582.
42. Simonian, P.L., Grillot, D.A., and Nuñez, G. (1997). Bcl-2 and Bcl-XL can differentially block chemotherapy-induced cell death. Blood 90, 1208-1216.
43. Sporeno, E., Savino, R., Ciapponi, L., Paonessa, G., Cabibbo, A., Lahm, A., Pulkki, K., Sun, R.X., Toniatti, C., Klein, B., and Ciliberto, G. (1996). Human interleukin-6 receptor super-antagonists with high potency and wide spectrum on multiple myeloma cells. Blood 87, 4510-4519.
44. Takeda, K., Noguchi, K., Shi, W., Tanaka, T., Matsumoto, M., YosHida, N., Kishimoto, T., and Akira, S. (1997). Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc. Natl. Acad. Sci. USA 94, 3801-3804.
45. Takemoto, S., Mulloy, J.C., Cereseto, A., Migone, T.S., Patel, B.K., Matsuoka, M., Yamaguchi, K., Takatsuki, K., Kamihira, S., White, J.D., et al. (1997). Proliferation of adult T cell leukemia/lymphoma cells is associated with the constitutive activation of JAK/STAT proteins. Proc. Natl. Acad. Sci. USA 94, 13897-13902.
46. Thompson, C.B. (1995). Apoptosis in the pathogenesis and treatment of disease. Science 267, 1456-1462.
47. Tu, Y., Renner, S., Xu, F., Fleishman, A., Taylor, J., Weisz, J., Vescio, R., Rettig, M., Berenson, J., Krajewski, S., et al. (1998). BCL-X expression in multiple myeloma: Possible indicator of chemoresistance. Cancer Res. 58, 256-262.
48. Turkson, J., Bowman, T., Garcia, R., Caldenhoven, E., de Groot, R.P., and Jove, R. (1998). Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol. Cell. Biol. 18, 2545-2552.
49. Weber-Nordt, R.M., Egen, C., Wehinger, J., Ludwig, W., Gouilleux-Gruart, V., Mertelsmann, R., and Finke, J. (1996). Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines. Blood 88, 809-816.
50. Wegenka, U.M., Buschmann, J., Lutticken, C., Heinrich, P.C., and Horn, F. (1993). Acute-phase response factor, a nuclear factor binding to acute-phase response elements, is rapidly activated by interleukin-6 at the post-translational level. Mol. Cell. Biol. 13, 276-288.
51. Xu, F.H., Sharma, S., Gardner, A., Tu, Y., Raitano, A., Sawyers, C., And Lichtenstein, A. (1998). Lnterleukin-6-induced inhibition of multiple myeloma cell apoptosis: Support for the hypothesis that protection is mediated via inhibition of the JNK/SAPK pathway. Blood 92, 241-251.
52. Yu, C.L., Meyer, D.J., Campbell, G.S., Lamer, A.C., Carter-Su, C., Schwanz, J.,and Jove, R. (1995). Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 269, 81-83.
53. Yu, C.L., Jove, R., and Burakoff, S.J. (1997). Constitutive activation of the Janus kinase-STAT pathway in T lymphoma overexpressing the Lck protein tyrosine kinase. J. Immunol. 159, 5206-5210.
54. Zhang, Q., Nowak, I., Vonderheid, E.C., Rook, A.H., Kadin, M.E., Nowell, P.C., Shaw, L.M., and Wasik, M.A. (1996). Activation of Jak/ STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and sezary syndrome. Proc. Natl. Acad. Sci. USA 93, 9148-9153.
55. Zhong, Z., Wen, Z., and Darnell, J.E. (1994). Stat3: A STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 264, 95-98.
56. Zong, C., Yan, R., August, A., Darnell, J.E., and Hanafusa, H. (1996). Unique signal transduction of Eyk: constitutive stimulation of the JAK-STAT pathway by an oncogenic receptor-type tyrosine kinase. EMBO J. 15, 4515-4525.